Tumor Targeting via siRNA-COG3 to Suppress Tumor Progression in Mice and Inhibit Cancer Metastasis and Angiogenesis in Ovarian Cancer Cell Lines.
Janat IjabiRoghayeh IjabiParisa RoozehdarZachary A KaminskyHemen Moradi-SardarehNajmeh TehranianNaveed AhmedPublished in: MicroRNA (Shariqah, United Arab Emirates) (2024)
Overall, by knockdown of the COG3 gene, MT1-MMP and YKL40 were dropped, leading to suppressed angiogenesis along with decreasing migration and proliferation. SiRNA-COG3 may be an ideal agent to consider for clinical trial assessment therapy for OC, especially when an antiangiogenic SNAR-pathway targeting drug.
Keyphrases
- cancer therapy
- clinical trial
- endothelial cells
- vascular endothelial growth factor
- drug delivery
- papillary thyroid
- signaling pathway
- genome wide
- wound healing
- squamous cell carcinoma
- high fat diet induced
- emergency department
- study protocol
- hyaluronic acid
- open label
- dna methylation
- skeletal muscle
- insulin resistance
- long non coding rna
- drug induced
- lymph node metastasis
- genome wide identification
- wild type